GLP-1 Therapies Newsletter
Issue #57October 5, 20267 studies
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
The obesity drug pipeline just got a lot more crowded—and a lot more effective.
This week brought phase 3 data on two next-generation receptor agonists, a landmark diabetes consensus that reshapes when to start these drugs, and a case report that every prescriber with chronic pain patients should read.
Retatrutide hits 25–35% weight loss in phase 3 — and that number matters 🎯
- Retatrutide is a triple agonist hitting three receptors at once: the same two targeted by tirzepatide, plus a glucagon receptor that dials up energy expenditure and liver metabolism.
- In the TRIUMPH-2 phase 3 trial (adults with obesity and type 2 diabetes), retatrutide produced weight loss in the 25–35% range — territory previously reserved for bariatric surgery.
- A companion New England Journal of Medicine paper on survodutide, a dual glucagon/GLP-1 agonist, reported up to 18.7% weight loss at 46 weeks in its phase 2 data, with phase 3 SYNCHRONIZE trials now underway.
Why it matters: The ceiling on pharmacological weight loss keeps rising. Retatrutide's numbers put it in a class that, until recently, only surgery could reach — which reframes the entire conversation about who needs an operation.
Key Findings
The ADA and EASD just rewrote the type 2 diabetes playbook 📋
- The 2026 ADA/EASD consensus now recommends starting SGLT2 inhibitors and/or GLP-1-based therapies potentially from the moment of diagnosis — not as add-ons after metformin fails.
- Earlier combination use of both drug classes is specifically flagged for patients who already have cardiovascular disease, chronic kidney disease, or heart failure.
💡 Earlier is now the official answer for type 2 diabetes drug sequencing.
Oral GLP-1 without fasting: safiglipron clears a phase 3 bar in China 💊
- In 284 adults with early type 2 diabetes, once-daily oral safiglipron (no fasting or dietary restrictions required) cut HbA1c by up to 1.45 percentage points more than placebo at 32 weeks.
- Over 70% of participants on the drug reached an HbA1c below 7.0%, versus 25% on placebo — a meaningful gap for a pill that skips the injection entirely.
💡 A no-fasting oral GLP-1 just matched injectable benchmarks in a controlled trial.
Semaglutide's kidney protection now has a mechanism 🔬
- A 52-week randomized trial used kidney biopsies and transcriptomics in 33 participants to look inside what semaglutide actually does to kidney tissue in type 2 diabetes with chronic kidney disease.
- The drug was associated with reduced vascular resistance, signs of slowed fibrosis progression, and fewer immune cells clustering around glomerular endothelial cells — concrete tissue-level signals, not just biomarker shifts.
💡 Semaglutide's kidney benefit now has tissue-level evidence behind it.
Tirzepatide + a pain pill = a dangerous combination no one flagged ⚠️
- A 53-year-old man on 180 mg/day of oral sustained-release morphine for 13 years developed life-threatening respiratory failure six weeks after starting tirzepatide — requiring 12 mg of naloxone to reverse.
- Two mechanisms likely converged: tirzepatide slows gastric emptying (disrupting the release profile of sustained-action morphine) and triggered dehydration-related kidney injury, which impaired clearance of morphine's active metabolite.
💡 GLP-1 drugs and chronic oral opioids may be a pharmacokinetic collision waiting to happen.
The 'GLP-1 eats your muscle' worry gets a more nuanced read 💪
- Across incretin therapy trials, roughly one-quarter to one-third of total weight lost is lean mass — a proportion comparable to other effective weight-loss interventions, including surgery and caloric restriction.
- Incretin drugs preferentially reduce fat mass and improve the lean-to-fat ratio, and are associated with improvements in physical function — which challenges the framing that lean mass loss equals clinical sarcopenia.
💡 Lean mass loss on GLP-1s looks like normal physiology, not muscle disease — for most patients.
Who loses the most weight on semaglutide? The predictors are getting clearer 🎯
- Women lose about 6% more body weight than men on semaglutide on average, and people without type 2 diabetes lose significantly more than those with it — the two most consistent predictors identified across current evidence.
- A higher maintenance dose (7.2 mg vs. the standard 2.4 mg) adds roughly 3% more weight loss, while age and starting BMI show no clear consistent relationship with response.
💡 Sex and diabetes status are the two most reliable predictors of semaglutide response so far.
Implications
The pipeline is delivering drugs that rival surgery for weight loss, while basic questions remain unanswered: who should get pharmacotherapy first versus an operation, how long combined regimens should run, and whether the lean mass lost during rapid weight loss is clinically meaningful or physiologically normal. The opioid interaction case makes the last question urgent.
Studies in this issue
Primary sources used for this newsletter.
- Retatrutide, a drug activating three hormone receptors, for treating obesitymain storyThe New England journal of medicine2026-09-30PMID 42814954
- Semaglutide's effects on kidney disease in type 2 diabetes in a controlled trialkey findingNature medicine2026-10-01PMID 42823485
- Rethinking Muscle Loss Concerns with Incretin Therapykey findingAdvances in therapy2026-09-28PMID 42804080
- Opioid Poisoning Linked to Tirzepatide in a Patient Taking Long-Term Oral Morphinekey findingCureus2026-09-29PMID 42807130
- Effects of the oral drug safiglipron on early type 2 diabetes in a controlled clinical trialkey findingNature medicine2026-09-29PMID 42811187
- Guidelines for Managing Type 2 Diabetes in 2026 from the American and European Diabetes Associationskey findingDiabetes care2026-10-02PMID 42825450
- Factors linked to how well semaglutide works for weight losskey findingFrontiers in endocrinology2026-10-02PMID 42824923
Continue reading
All GLP-1 Therapies issuesGet the next GLP-1 Therapies issue
Seven papers, once a week. Free.